| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oleocanthal is essentially found ONLY in: Fresh, unrefined extra-virgin olive oil (EVOO) It is part of the pungent, throat-stinging phenolic fraction that disappears in refined oils. Oleuropein (OLEU) — a secoiridoid polyphenol from olive leaf and olive fruit/extra-virgin olive oil; major in-vivo related phenolic is hydroxytyrosol (via hydrolysis/metabolism). Sources: olive leaf extract (standardized to oleuropein), EVOO phenolics. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human data show absorption/metabolism after oral olive leaf extract; circulating forms are largely metabolites (and hydroxytyrosol-related), with limited free parent compound exposure. :contentReference[oaicite:0]{index=0} In-vitro vs oral exposure: Many direct “anticancer” cytotoxic effects occur at micromolar concentrations that may exceed typical systemic exposure from supplements/foods (high concentration only for direct tumor cytotoxicity in many models). :contentReference[oaicite:1]{index=1} Clinical evidence status: Nutraceutical/food bioactive with human data mainly for cardiometabolic/inflammation endpoints; oncology evidence largely preclinical/adjunct-hypothesis (no oncology approval). Also available as a supplement usually labeled as Olive Leaf Extract. (20-50% concentrations)- commonly used in CSC (Cancer Stem Cell) research. Main CSC mechanisms: -Inhibits Wnt/β-catenin — a core CSC survival pathway -↓ALDH (Reduces ALDH-high CSC subpopulations) -downregulates stemness geens: SOX2/OCT4/Nanog → reduced sphere formation/self-renewal. Oleuropein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Oleuropein — AD relevance: Oleuropein/olive leaf phenolics show neuroprotection in models via oxidative- and heat-shock/proteostasis stress responses, with reported reduction of Aβ and tau proteotoxicity in preclinical systems; human AD disease-modifying evidence is not established. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human absorption/metabolism supports systemic exposure mainly as metabolites; brain relevance likely chronic/adaptive. :contentReference[oaicite:9]{index=9} Clinical evidence status: Predominantly preclinical for AD mechanisms; limited AD-specific clinical endpoint evidence. Oleuropein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| HDAC3 is an enzyme belonging to the class I histone deacetylases and plays a key role in transcriptional regulation by removing acetyl groups from histone tails. This deacetylase activity leads to chromatin condensation and generally results in transcriptional repression. HDAC3 is involved in multiple cellular processes, including cell cycle regulation, apoptosis, and differentiation. HDAC3 is frequently found to be overexpressed in several cancer types, including breast, colorectal, liver, lung, and hematological malignancies. Elevated HDAC3 levels have been associated with the repression of tumor suppressor genes and deregulation of proliferative pathways. |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:375 Target#:1023 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid